BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 749195)

  • 21. [Circulating immune complexes and necrotizing vasculitis].
    Tappeiner G; Wolff K
    Hautarzt; 1979 Dec; 30(12):628-33. PubMed ID: 398359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes of serum complement and of circulating immune complexes in patients with multiple sclerosis.
    Cojocaru M; Serbănescu A; Cojocaru IM
    Rom J Intern Med; 1993; 31(2):131-7. PubMed ID: 8268831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. C1q-binding substances in peripheral lymph in bronchial carcinoma.
    Heier HE; Sokolowski JA; Solheim OP
    Lymphology; 1978 Dec; 11(4):170-3. PubMed ID: 739789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Control of C1 activation by nascent C3b and C4b: a mechanism of feedback inhibition.
    Ziccardi RJ
    J Immunol; 1986 May; 136(9):3378-83. PubMed ID: 3485688
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Activation of the alternative complement pathway in pleural fluid of patients with pneumonia].
    Aguado MT; Celada A
    Allergol Immunopathol (Madr); 1982; 10(3):215-20. PubMed ID: 6924537
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complexes between C1q and C3 or C4: novel and specific markers for classical complement pathway activation.
    Wouters D; Wiessenberg HD; Hart M; Bruins P; Voskuyl A; Daha MR; Hack CE
    J Immunol Methods; 2005 Mar; 298(1-2):35-45. PubMed ID: 15847795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Studies on the haemolytic activity of circulating C1q-C3/C4 complexes.
    Wouters D; Brouwer MC; Daha MR; Hack CE
    Mol Immunol; 2008 Apr; 45(7):1893-9. PubMed ID: 18054386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The complement fixing ability of putative circulating immune complexes in rheumatoid arthritis and its relationship to extra-articular disease.
    Bourke BE; Moss IK; Mumford P; Horsfall A; Maini RN
    Clin Exp Immunol; 1982 Jun; 48(3):726-32. PubMed ID: 6981475
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The interaction of human plasma fibronectin with a subunit of the first component of complement, C1q.
    Pearlstein E; Sorvillo J; Gigli I
    J Immunol; 1982 May; 128(5):2036-9. PubMed ID: 6801128
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of immune precipitation by purified classical pathway complement components.
    Naama JK; Hamilton AO; Yeung-Laiwah AC; Whaley K
    Clin Exp Immunol; 1984 Nov; 58(2):486-92. PubMed ID: 6333948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo degradation of rat C1q induced by intravenous injection of soluble IgG aggregates.
    Veerhuis R; van Es LA; Daha MR
    Immunology; 1985 Apr; 54(4):801-10. PubMed ID: 3872261
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Local immunotherapy with interferon-alpha in metastatic pleural and peritoneal effusions: correlation with immunologic parameters.
    Stathopoulos GP; Baxevanis CN; Papadopoulos NG; Zarkadis IK; Papacostas P; Michailakis E; Tsiatas ML; Papamichail M
    Anticancer Res; 1996; 16(6B):3855-60. PubMed ID: 9042270
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Complement components and their activation products in pleural fluid.
    Salomaa ER; Viander M; Saaresranta T; Terho EO
    Chest; 1998 Sep; 114(3):723-30. PubMed ID: 9743157
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune complex vasculitis as a cause of ascites and pleural effusions in systemic lupus erythematosus.
    Schocket AL; Lain D; Kohler PF; Steigerwald J
    J Rheumatol; 1978; 5(1):33-8. PubMed ID: 147941
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Evaluation of the role of circulating antigen-antibody complexes in the pathogenesis of glomerular nephropathies].
    Favre H; Nydegger U; Zubler R; Mulli JC; Lambert PH; Cruchaud A
    Schweiz Med Wochenschr; 1977 Dec; 107(48):1781-3. PubMed ID: 929139
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circulating immune complexes and complement levels in hemophilic children.
    Verroust F; Adam C; Kourilsky O; Allain JP; Verroust P
    J Clin Lab Immunol; 1981 Sep; 6(2):127-30. PubMed ID: 6912882
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 125I-C1q binding activity of soluble antigen-antibody complexes formed in vitro.
    Soltis RD; Hasz DE
    J Clin Lab Immunol; 1982 Nov; 9(2):121-31. PubMed ID: 6984078
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complement activation in fetuses: assessment by the levels of complement components and split products in cord blood.
    Miyano A; Nakayama M; Fujita T; Kitajima H; Imai S; Shimizu A
    Diagn Clin Immunol; 1987; 5(2):86-90. PubMed ID: 3497734
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serial measurement of circulating immune complexes in the sera of patients with leukaemia.
    Mód A; Carpentier N; Füst G; Lambert PH; Miescher P; Hollán SR
    J Clin Lab Immunol; 1980 Jul; 4(1):15-20. PubMed ID: 7007648
    [TBL] [Abstract][Full Text] [Related]  

  • 40. C3, C4, and the terminal complement complex differ from C1q by binding predominantly to the antigenic part of solid phase immune complexes.
    Garred P; Michaelsen TE; Aase A; Mollnes TE
    J Immunol; 1990 Jan; 144(1):198-203. PubMed ID: 2295791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.